ClinicalTrials.gg
Status unknownNCT01504334Updated Feb 7, 2012

Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)

A Phase 2 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Beijing Kawin Technology Share-Holding Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-07.

Sponsored by Beijing Kawin Technology Share-Holding Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Planned enrollment
13th of 21
80 · median 89
Started
2012
the only one that year
Phase 2
6 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
1 of 21
Beijing Kawin Technology Share-Holding Co., Ltd.

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 13th largest by planned enrollment, is the only one that started in 2012, is one of 6 in phase 2, and was the 6th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of lung disease characterized by fibrosis of the supporting framework (interstitium) of the lungs. By definition, the term is used only when the cause of the pulmonary fibrosis is unknown ("idiopathic"). Microscopically, lung tissue from patients shows a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). UIP is therefore the pathologic counterpart of IPF.Idiopathic pulmonary fibrosis is characterized by radiographically evident interstitial infiltrates predominantly affecting the lung bases and by progressive dyspnea and worsening of pulmonary function. No therapy has been clearly shown to prolong survival. The current strict definition of idiopathic pulmonary fibrosis provides a new focus for basic and clinical research that will improve insight into the pathogenesis of this disorder and stimulate the development of novel therapies.

Pirfenidone has proven antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of pulmonary fibrosis, although its precise mechanism of action remains unclear. It attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokines such as transforming growth factor-β. It is also shown to slow tumor cell proliferation by inhibiting fibroblast growth factor, epidermal growth factor and platelet-derived growth factor.

Pirfenidone has not been widely approved for clinical use in China, in this study, safety and efficacy were evaluated to see if pirfenidone has a significant advantage over placebo in terms of improving lung function and life quality etc. (see primary and secondary criteria) or slows down the deterioration of lung function in Chinese subjects diagnosed with IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed;
  2. 18-75 years of age;
  3. Clinically or multidisciplinarily diagnosed idiopathic pulmonary fibrosis(see 2011 guidance );
  4. Resting state PaO2≥50mg, FVC%≥45% normal predicted value and DLCO≥30% normal predicted value.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to pirfenidone;
  2. Dyspnea symptoms relieved in the past 6 months;
  3. Patients in acute exacerbation phase;
  4. Diabetic patients whose fasting venous glucose >11.1 mmol/L;
  5. Patients with malignant tumor and hemorrhagic diseases;
  6. Patients with serious underlying pulmonary disease;
  7. Patients with serious heart disease( class Ⅲ-Ⅳ), liver disease( or AST 2 times above the upper level of normal value range), kidney disease(Cr above the upper level of normal value range);
  8. Patients who has taken Acetylcysteine in the past 3 months;
  9. Patients who has taken Prednisone>15mg/day(or other equivalent amount of ) and/or Immunosuppresants in the past 3 months;
  10. Patients who has taken interferon, penicillamine, colchine or other agents for the treatment of IPF;
  11. Pregnant or lactating women;
  12. Participated in other clinical trials in the past 1 month;
  13. The investigator assessed as inappropriate to participate in this clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Pirfenidone(200mg)

    Pirfenidone(200mg)tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets(600mg)will be taken once a day, 1 tablet each time from the first to the 48th week.

    Drug: Pirfenidone

  • Placebo comparator
    Placebo (without active ingredient)

    Drug: Placebo

Interventions

  • Pirfenidone(200mg)tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets(600mg)will be taken once a day, 1 tablet each time from the first to the 48th week.

  • DrugPlacebo

    Placebo(without active ingredient) tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets(600mg)will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.

06

What researchers measure

Primary outcomes

  1. Changes in forced vital capacity (FVC)

    Changes in FVC from 48 weeks to baseline

    Time frame: 48 weeks

Secondary outcomes

  1. Changes in lung function (including arterial blood gas analysis)

    Lung function will be assessed as improved/stabilized/exacerbated from 48 weeks to baseline.

    Time frame: 48 weeks

  2. Acute Exacerbation during the whole treatment procedure(frequency and severity)

    The following clinical deterioration symptoms within a month that cannot be explained by other reasons will be assessed as acute exacerbation: 1. Aggravated dyspnea; 2. Newly discovered chest interstitial lung abnormality by radiograph/HRCT, without pneumothorax or pleural effusion; 3. PaO2 decreases ≥10mm Hg,heart failure or pulmonary embolism excluded. Acute Exacerbation can be assessed if 1 and 2 appear or 1 and 3 appear.

    Time frame: 48 weeks

  3. Progression-free time

    Progression of disease during the whole study period is defined as follows: 1. Progressive dyspnea (objective evaluation); 2. FVC absolute value progressively and constantly decreases compared with baseline value; 3. DLCO absolute value (after hemoglobin calibration) progressively and constantly decreases compared with baseline value; 4. Fibrosis progressive deterioration by HRCT examination; 5. Acute Exacerbation; 6. Death caused by respiratory failure.

    Time frame: 48 weeks

  4. 6 Minute Walk Test (6MWT ): Changes in 6 minute walk distance (6MWD) and SpO2 from 48 weeks to baseline

    Method: The walking test is conducted in a corridor 33 meters long. The patient is instructed to "walk from end to end, covering as much ground as they can in the allotted time". The total distance ambulated in meters during the 6-minute walk test and the number of rest stops is recorded. 6MWD, weight, heart rate, BP, SpO2, and a self-reported rating of perceived exertion \[modified Borg RPE scale rating (0 to 10 scale)\] is recorded after the walk.

    Time frame: 48 weeks

  5. Borg RPE scale rating improvement rate during the whole study period

    Patient percentage whose Borg RPE scale rating improves more than 1 level.

    Time frame: 48 weeks

  6. Lung interstitial change observed by HRCT

    Changes in HRCT lung interstitial evaluation score from 48 weeks to baseline

    Time frame: 48 weeks

  7. Life quality: assessed by St. George respiratory questionnaire (SGRQ).

    Life quality will be assessed as improved if SGRQ single or total score increased \>4% when completing the trial; Life quality will be assessed as stabilized if SGRQ single or total score changes within the range of 4% when completing the trial; Life quality will be assessed as exacerbated if SGRQ single or total score decreased \>4% when completing the trial.

    Time frame: 48 weeks

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijng 100032, China
    Recruiting
    • Zuojun Xu, MD · Contactxuzj@hotmail.com · 010-65295039
    • Zuojun Xu, MD · Principal investigator
08

References and documents

Publications

  • Huang H, Dai HP, Kang J, Chen BY, Sun TY, Xu ZJ. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (Baltimore). 2015 Oct;94(42):e1600. doi: 10.1097/MD.0000000000001600. PubMed 26496265 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Nov 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2011
First posted
Jan 5, 2012
Start
Jan 2012
Primary completionEst.
Nov 2012
CompletionEst.
Mar 2013
Last update
Feb 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01504334
Lead sponsor
Beijing Kawin Technology Share-Holding Co., Ltd.
Responsible party
Zuojun Xu (Chief Physician, Beijing Kawin Technology Share-Holding Co., Ltd.) — Principal investigator
First posted
Jan 5, 2012
Start date
Jan 2012
Primary completion
Nov 2012 (estimated)
Completion
Mar 2013 (estimated)
Last update
Feb 7, 2012

Study contacts

Xu Zuojun, MD
Contact
xuzj@hotmail.com
+86-10-65295039
Xu Zuojun, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion